Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: Biological and methodological considerations

Journal of Clinical Pathology

Volumn 64, Issue 3, 2011, Pages 200-207

  Lambein, Kathleen ^a,b   Praet, Marleen ^a,b   Forsyth, Ramses ^b   Van Den Broecke, Rudy ^b   Braems, Geert ^b   Matthys, Bart ^b   Cocquyt, Veronique ^b   Denys, Hannelore ^b   Pauwels, Patrick ^a   Libbrecht, Louis ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME ENUMERATION PROBE 17 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GENE PRODUCT; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CEP17 GENE; CLINICAL FEATURE; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; HER2 GENE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE DOSAGE; GENES, ERBB-2; GENES, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79951949643     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.084863     Document Type: Article

References (29)

1. Sauter G, Lee J, Bartlett JMS, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
2. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-64.
3. Ko H, Seol H, Kim WY, et al. Ongoing debates in the assessment of the HER2 status in breast cancer: a comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines. Basic Appl Pathol 2008;1:182-8.
4. Marchiò C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24.
5. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009;22:1169-75.
6. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010;120:1-7.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of clinical oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
8. Tavassoli FA, Devilee P. Pathology and Genetics Tumours of the Breast and Female Genital Organs. Geneva: World Health Organization, 2003.
9. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of umors. 7th edn. Hoboken: Wiley-Blackwell, 2009.
10. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6. (Pubitemid 23046895)
11. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-12.
12. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307-15.
13. Owens MA, Horten BC. Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9. (Pubitemid 38821193)
14. Albarracin C, Edgerton ME, Gilcrease MZ, et al. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med 2010;134:162-3.
15. Hsu CY, Li AF, Yang CF, et al. Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer. Arch Pathol Lab Med 2010;134:162.
16. Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13:6404-9. (Pubitemid 350075030)
17. Tubbs R, Barlow WE, Budd GT, et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009;27:3881-6.
18. Collins N, Faulkes C, Ping B, et al. A rapid scoring technique for HER2 assessment following silver in situ hybridisation is accurate, robust and reliable. J Clin Pathol 2010;63:661-2.
19. Ross JS. Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference? J Clin Oncol 2010;28:4293-5.
20. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
21. Giuliani R, Durbecq V, Di Leo A, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer. Eur J Cancer 2007;43:725-35. (Pubitemid 46509445)
22. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-9.
23. Purdie CA, Jordan LB, McCullough JB, et al. HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 2010;56:702-7.
24. Baehner FL, Achacoso N, Maddala T, et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010;28:4300-6.
25. Colpaert C, Salgado R. Belgian guidelines for HER2/neu testing in breast cancer. Belg J Med Oncol 2007;1:22-9.
26. Arena V, Pennacchia I, Carbone A, et al. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test? J Clin Oncol 2009;27:e8.
27. Hammond E, Wolff A, Hayes D, et al. Reply to G. Sauter et al. J Clin Oncol 2009;37:e153-4.
28. Arena V, Pennacchia I, Monego G, et al. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies. J Clin Oncol 2010;28:e83-4.
29. Bartholdi MF. Nuclear distribution of centromeres during the cell cycle of human diploid fibroblasts. J Cell Sci 1991;99:255-63. (Pubitemid 21925014)